Accretion Nutraveda IPO
₹122 – ₹122 · Issue Size ₹24.77 CrIPO Overview
Business Model
Total Revenue" It is sum of Revenue from Operations and Other Income 20 Term Description "EBITDA" EBITDA is calculated as profit for the year/ period, plus tax expenses (consisting of current tax, deferred tax and current taxes relating to earlier years), finance costs and depreciation and amortization expenses, less other income. "EBITDA Margin (%)" Calculated as EBITDA divided by Revenue from Operations. "PAT" or "Profit After Tax" Profit for the period/year as appearing in the Restated Financial Statement. "PAT Margin (%)" Calculated as profit for the year/period as a percentage of Revenue from Operations. "Net profit ratio" Net profit ratio is an indicator of the overall profitability and financial performance of our business/company i.e. profit after tax as a % of Total Revenue fro
- Presently, our Company operates its business through two primary sales streams:
IPO Timeline
Objects of the Issue
The details of the proceeds of the Fresh Issue are summarized below: Particulars Amount (₹ in Lakhs)(1) Gross Proceeds of the Issue Less: Issue related expenses Net proceeds of the Issue after deducting the Issue related expenses to be borne by the company ("Net Proceeds") (1)To be finalized on determination of the Issue Price and updated in the prospectus prior to filing with the RoC. Utilization of Net Issue Proceeds The Net Proceeds are proposed to be utilized in accordance with the details p
Strengths & Weaknesses
Strengths
- Presently, our Company operates its business through two primary sales streams:
Management & Promoters
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| Accretion Nutraveda IPO | — | — |
| Dated: January | 20.0x | — |
| Please read Section and Section of the Companies Act | 26.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| September 2025 | ₹0.17 Cr | — | ₹0.12 Cr | ₹2.57 Cr |
| March 2025 | ₹0.18 Cr | — | ₹0.13 Cr | ₹16.35 Cr |
| March 2024 | ₹0.19 Cr | — | ₹0.14 Cr | ₹10.86 Cr |
| March 2023 | ₹0.2 Cr | — | ₹-0.01 Cr | ₹4.64 Cr |
| 2013 | — | — | — | ₹4.06 Cr |
About
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company serves its customers in India as well as in international countries like Sri Lanka, Singapore, and the USA. The firm blends Ayurvedic and science to offer treat
Key Industry Regulations and Policies", "Statement of Possible Special Tax Benefits", "Restated Financial Information", "Basis for Issue Price", "History and Certain Corporate Matters", "Restriction on Foreign Ownership of Indian Securities", "Other Regulatory and Statutory Disclosures", "Outstanding Litigations and Material Developments" and "Main provisions of the Articles of Association" beginning on pages 162, 222, 159, 283, 149, 237, 443, 375, 359 and 446 respectively, shall have the meaning ascribed to them in the relevant section. General Terms Term Description "Our Company", "the C
| Exchange | NSE |
| Issue Type | sme |
| Face Value | ₹10 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.